Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial
- Jeffrey M. Saland
- , John C. Lieske
- , Jaap W. Groothoff
- , Yaacov Frishberg
- , Hadas Shasha-Lavsky
- , Daniella Magen
- , Shabbir H. Moochhala
- , Eva Simkova
- , Martin Coenen
- , Wesley Hayes
- , Julien Hogan
- , Anne Laure Sellier-Leclerc
- , Richard Willey
- , John M. Gansner
- , Sally Anne Hulton
- Icahn School of Medicine at Mount Sinai
- Mayo Clinic Rochester, MN
- University of Amsterdam
- Shaare Zedek Medical Center
- Western Galilee Medical Center of Nahariya
- Rambam Health Care Campus Israel
- Royal Free London NHS Foundation Trust
- Al Jalila Children's Hospital
- University of Bonn
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Hôpital Robert Debré AP-HP
- Hospices civils de Lyon
- Alnylam Pharmaceuticals
- Birmingham Women's and Children's NHS Foundation Trust
Research output: Contribution to journal › Article › peer-review
15
Scopus
citations